c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.

Giatromanolaki, A

c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. [electronic resource] - Anticancer research - 997-1004 p. digital

Publication Type: Journal Article

0250-7005


Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Squamous Cell--blood supply
Cisplatin--administration & dosage
Combined Modality Therapy
Female
Fluorouracil--administration & dosage
Follow-Up Studies
Head and Neck Neoplasms--blood supply
Humans
Leucovorin--administration & dosage
Male
Methotrexate--administration & dosage
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Prognosis
Proto-Oncogene Proteins c-bcl-2--analysis
Receptor, ErbB-2--analysis
Survival Analysis
Time Factors
Tumor Suppressor Protein p53--analysis